METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
1 - 6 . (canceled)
7 . A method of diagnosing a subject having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder characterized by:
(a) the presence, distribution, or level of an isocitrate dehydrogenase 2 enzyme having a mutation at residue 140 wherein the arginine residue has been replaced with a glutamine residue (IDH2-R140Q), which has 2HG (2-hydroxyglutarate) neoactivity, wherein 2HG neoactivity is the ability to convert alpha ketoglutarate to 2-hydroxyglutarate; or
(b) elevated levels of 2HG due to the presence of an IDH2-R140Q mutant enzyme having 2HG neoactivity,
wherein said method comprises analyzing the presence, distribution, or level of 2HG in a tissue, product, or bodily fluid of said subject by a chromatographic method, wherein an increased presence, distribution, or level of 2HG indicates the presence of the cell proliferation-related disorder, thereby diagnosing the subject for the cell proliferation-related disorder.
8 . (canceled)
9 . The method of claim 7 wherein said cell proliferation-related disorder is selected from the group consisting of acute lymphoblastic leukemia and acute myelogenous leukemia.
10 . The method of claim 7 , wherein said bodily fluid is blood, plasma, or urine.
11 . The method of claim 7 , wherein the chromatographic method is LC-MS.
12 . The method of claim 7 , wherein the chromatographic method is GC-MS.
13 - 18 . (canceled)